贝瑞基因(000710.SZ)：上半年净亏损2724.25万元

Core Viewpoint - Berry Genomics (000710.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 447 million yuan, representing a year-on-year decrease of 18.91% [1] - The net profit attributable to shareholders of the listed company was -27.24 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -28.59 million yuan [1] - The basic earnings per share were -0.0771 yuan [1]